How should balanitis be treated in a patient taking a gliflozin (SGLT2‑inhibitor)?

Management of Balanitis in Patients Taking SGLT2 Inhibitors

Treat balanitis with topical antifungals while continuing the SGLT2 inhibitor in most cases, because the cardiovascular and renal mortality benefits of these drugs far outweigh the inconvenience of a mild, easily treatable genital infection.

Understanding the Mechanism and Risk

• SGLT2 inhibitors cause glycosuria (urinary glucose excretion of 200–300 kcal/day), which creates a favorable environment for fungal overgrowth in the genital area 1, 2.
• Balanitis occurs in approximately 4–6% of men taking SGLT2 inhibitors, compared with <1% on placebo 3.
• The infection is typically candidal (90% of cases), presenting as erythematous areas on the glans penis with pruritus or irritation 4, 2, 5.
• Most infections are mild to moderate in severity and respond readily to standard antifungal therapy without requiring drug discontinuation 3, 6.

First-Line Treatment

Continue the SGLT2 inhibitor and initiate topical antifungal therapy immediately:

• Miconazole 2% cream applied twice daily for 7 days is the first-line topical treatment 4, 2.
• Tioconazole 6.5% ointment as a single application is an equally effective alternative 4.
• Clotrimazole 1% cream applied twice daily for 7–14 days may also be used 4.

Escalation for Severe or Resistant Cases

• Oral fluconazole 150 mg as a single dose should be prescribed when topical therapy fails or when the infection is severe 4, 2.
• Consider a longer treatment course (7–14 days of topical therapy) in patients with diabetes, as compromised immune function may delay clearance 4.

When to Discontinue the SGLT2 Inhibitor

Permanent discontinuation is rarely necessary and results in rapid loss of cardiovascular and renal protection 6. Stop the drug only if:

• The infection is recurrent despite optimal antifungal therapy and meticulous hygiene 6.
• The patient develops complicated infection (candidemia, prostatic abscess, or necrotizing fasciitis), which is exceedingly rare 7.
• The patient has underlying urogenital anatomical abnormalities (severe phimosis, urethral stricture, bladder diverticula) that predispose to recurrent or complicated infection 7.

Preventive Measures and Patient Education

• Instruct patients to cleanse the genital area gently with warm water only, avoiding strong soaps, and to keep the area dry after washing 4.
• Educate patients to report symptoms early (redness, itching, irritation) so treatment can be initiated before the infection worsens 6.
• Optimize glycemic control to reduce the severity of glycosuria and lower infection risk 4.

Follow-Up and Monitoring

• Re-evaluate the patient if symptoms persist or recur within 2 months 4, 2.
• If the infection recurs, assess the sexual partner for candidal infection and consider partner treatment, as vulvovaginal candidiasis can serve as a reservoir for reinfection 4.
• Obtain a fungal culture if the infection fails to respond to standard therapy, to identify resistant organisms (e.g., Candida glabrata) that may require alternative antifungals 7.

Distinguishing Candidal Balanitis from Other Conditions

• Dermatophyte (tinea) infection presents as well-demarcated, scaly plaques with a raised border and central clearing, rather than the glazed erythema of candidiasis 4.
• Lichen sclerosus (balanitis xerotica obliterans) appears as white, atrophic patches and requires biopsy for diagnosis; it is treated with clobetasol propionate 0.05% cream twice daily for 2–3 months, not antifungals 4.
• Biopsy is mandatory for any lesion that is pigmented, indurated, fixed, ulcerated, or fails to respond to antifungal therapy, to exclude malignancy 4.

Balancing Risks and Benefits

• The cardiovascular mortality reduction (38% with empagliflozin), heart-failure hospitalization reduction, and slowing of CKD progression provided by SGLT2 inhibitors are life-saving benefits that should not be forfeited for a mild, treatable infection 1.
• Discontinuation of the SGLT2 inhibitor eliminates these protective effects within weeks, exposing the patient to increased risk of cardiovascular death and renal failure 6.
• Resumption of therapy should occur as soon as the infection is controlled, unless severe or persistent contraindications exist 6.

Common Pitfalls to Avoid

• Do not discontinue the SGLT2 inhibitor at the first episode of balanitis; most cases resolve with simple topical therapy and do not recur 3, 6.
• Do not delay antifungal treatment while waiting for culture results; empiric therapy should be started immediately based on clinical presentation 4.
• Do not prescribe tetracycline antibiotics if bacterial superinfection is suspected in a patient under 8 years of age, due to risk of permanent tooth discoloration 4.